AbiVax’s Partnering Prospects For MicroRNA-based Drug Boosted By Rheumatoid Arthritis Data

Phase IIa RA Results Build On Ulcerative Colitis Promise

 
• By Sten Stovall

Now that AbiVax's novel anti-inflammatory ABX464 has demonstrated solid safety and efficacy in rheumatoid arthritis and ulcerative colitis, the French biotech is exploring additional programs in chronic inflammatory indications – and looking for a partner.

AbiVax reported excellent Phase IIa Clinical Safety And Efficacy Results in RA With 50mg ABX464 • Source: Alamy

More from Clinical Trials

More from R&D